GlassScriptPhysician profile
Miles C Layton
NPI 1790948669
$6,406.97
in general payments reported to CMS, 2019-2025
44 companies · $639 in 2025
The $639 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $542 · 2020: $709 · 2021: $2,134 · 2022: $973 · 2023: $756 · 2024: $653 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,048.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $1,344.74 | 2020-2021 | |
| Abbvie INC. | $1,169.99 | 2021-2025 | |
| Pfizer INC. | $587.84 | 2019-2025 | |
| Lilly USA, LLC | $534.73 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $296.26 | 2019-2025 | Rybelsus, Ozempic |
| Takeda Pharmaceuticals U.S.A., INC. | $236.34 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $194.94 | 2019-2023 | |
| Corium, LLC | $163.74 | 2022-2025 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $155.07 | 2022 | |
| Shire North American Group INC | $150.49 | 2019 | |
| Supernus Pharmaceuticals, INC. | $137.56 | 2021-2025 | Qelbree, Qelbree |
| Antares Pharma, INC. | $127.80 | 2019-2020 | |
| Amarin Pharma, INC. | $118.17 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $107.22 | 2019-2025 | Farxiga, Airsupra |
| Tris Pharma INC | $99.80 | 2023-2025 | Dyanavel Xr |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miles Layton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.